RS62801B1 - Aminotriazolopiridini kao inhibitori kinaze - Google Patents
Aminotriazolopiridini kao inhibitori kinazeInfo
- Publication number
- RS62801B1 RS62801B1 RS20220021A RSP20220021A RS62801B1 RS 62801 B1 RS62801 B1 RS 62801B1 RS 20220021 A RS20220021 A RS 20220021A RS P20220021 A RSP20220021 A RS P20220021A RS 62801 B1 RS62801 B1 RS 62801B1
- Authority
- RS
- Serbia
- Prior art keywords
- pyridin
- triazolo
- amino
- methyl
- carboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762458144P | 2017-02-13 | 2017-02-13 | |
| PCT/US2018/017755 WO2018148626A1 (en) | 2017-02-13 | 2018-02-12 | Aminotriazolopyridines as kinase inhibitors |
| EP18707498.4A EP3580220B1 (en) | 2017-02-13 | 2018-02-12 | Aminotriazolopyridines as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS62801B1 true RS62801B1 (sr) | 2022-02-28 |
Family
ID=61283335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220021A RS62801B1 (sr) | 2017-02-13 | 2018-02-12 | Aminotriazolopiridini kao inhibitori kinaze |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10913738B2 (OSRAM) |
| EP (1) | EP3580220B1 (OSRAM) |
| JP (1) | JP7097373B2 (OSRAM) |
| KR (1) | KR102549952B1 (OSRAM) |
| CN (1) | CN110520423B (OSRAM) |
| AU (1) | AU2018217488B2 (OSRAM) |
| BR (1) | BR112019016635A2 (OSRAM) |
| CA (1) | CA3053484A1 (OSRAM) |
| CY (1) | CY1124978T1 (OSRAM) |
| DK (1) | DK3580220T3 (OSRAM) |
| EA (1) | EA039808B1 (OSRAM) |
| ES (1) | ES2902676T3 (OSRAM) |
| HR (1) | HRP20212000T1 (OSRAM) |
| HU (1) | HUE057801T2 (OSRAM) |
| IL (1) | IL268614B (OSRAM) |
| LT (1) | LT3580220T (OSRAM) |
| MA (1) | MA47460A (OSRAM) |
| MX (1) | MX378515B (OSRAM) |
| PL (1) | PL3580220T3 (OSRAM) |
| PT (1) | PT3580220T (OSRAM) |
| RS (1) | RS62801B1 (OSRAM) |
| SG (1) | SG11201907335UA (OSRAM) |
| SI (1) | SI3580220T1 (OSRAM) |
| SM (1) | SMT202200001T1 (OSRAM) |
| WO (1) | WO2018148626A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3580220B1 (en) * | 2017-02-13 | 2021-11-17 | Bristol-Myers Squibb Company | Aminotriazolopyridines as kinase inhibitors |
| WO2019089442A1 (en) * | 2017-10-30 | 2019-05-09 | Bristol-Myers Squibb Company | Aminoimidazopyridines as kinase inhibitors |
| MX2020007531A (es) | 2018-01-26 | 2020-09-09 | Bristol Myers Squibb Co | Aminopirrolotriazinas como inhibidores de cinasa. |
| SG11202100130QA (en) | 2018-07-09 | 2021-02-25 | Lieber Institute Inc | Pyridine carboxamide compounds for inhibiting nav1.8 |
| KR102840599B1 (ko) * | 2018-07-09 | 2025-07-29 | 리버 인스티튜트, 아이엔씨 | Nav1.8을 억제하기 위한 피리다진(PYRIDAZINE) 화합물 |
| WO2020056072A1 (en) | 2018-09-13 | 2020-03-19 | Bristol-Myers Squibb Company | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) |
| US12084426B2 (en) * | 2018-09-13 | 2024-09-10 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| SG11202108064XA (en) * | 2019-01-25 | 2021-08-30 | Beijing Scitech Mq Pharmaceuticals Ltd | Acylamino bridged heterocyclic compound, and composition and application thereof |
| EP3943488A4 (en) * | 2019-03-22 | 2022-09-07 | Genfleet Therapeutics (Shanghai) Inc. | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND METHOD FOR PREPARATION AND PHARMACEUTICAL USE |
| MX2022003769A (es) | 2019-10-03 | 2022-04-20 | Bristol Myers Squibb Co | Indazol carboxamidas como inhibidores de cinasas. |
| AU2021219832B9 (en) * | 2020-02-13 | 2024-02-15 | Genfleet Therapeutics (Shanghai) Inc. | Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof |
| CN114230565B (zh) * | 2020-09-09 | 2023-10-27 | 成都奥睿药业有限公司 | 5-取代吲哚3-酰胺衍生物及其制备方法和用途 |
| CN114262322A (zh) * | 2020-09-16 | 2022-04-01 | 中国科学院上海有机化学研究所 | 一类细胞程序性坏死抑制剂及其制备方法和用途 |
| AR123793A1 (es) * | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
| TWI824626B (zh) * | 2021-08-02 | 2023-12-01 | 大陸商勁方醫藥科技(上海)有限公司 | Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型 |
| WO2023018643A1 (en) | 2021-08-10 | 2023-02-16 | Abbvie Inc. | Nicotinamide ripk1 inhibitors |
| TW202345852A (zh) | 2022-03-16 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠雜環類化合物、其製備方法及其在醫藥上的應用 |
| CN114989079B (zh) * | 2022-06-21 | 2023-06-23 | 中国药科大学 | Ripk1激酶靶点抑制剂及其医药用途 |
| AR131541A1 (es) | 2023-01-07 | 2025-04-09 | Syngenta Crop Protection Ag | Compuestos de carboxamida novedosos |
| AR133939A1 (es) * | 2023-09-27 | 2025-11-19 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de cinasa |
| WO2025109114A1 (en) | 2023-11-24 | 2025-05-30 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2025149637A1 (en) | 2024-01-12 | 2025-07-17 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2025149629A1 (en) | 2024-01-12 | 2025-07-17 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006004702A1 (en) * | 2004-06-25 | 2006-01-12 | Amgen Inc. | Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases |
| US8008481B2 (en) * | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
| ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| US8865699B2 (en) | 2007-11-27 | 2014-10-21 | Cellzome Ltd. | Amino triazoles as PI3K inhibitors |
| WO2010007100A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
| WO2010057877A1 (en) | 2008-11-18 | 2010-05-27 | Cellzome Limited | 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors |
| US8598163B2 (en) | 2009-02-04 | 2013-12-03 | Vitae Pharmaceuticals, Inc. | Derivatives of [1,3]Oxazin-2-one useful for the treatment of metabolic diseases such as lipid disorders |
| EP2897949B1 (en) | 2012-09-18 | 2018-01-10 | Bristol-Myers Squibb Company | Iap antagonists |
| CN105246891A (zh) | 2013-06-10 | 2016-01-13 | 拜耳制药股份公司 | 用于治疗癌症的新化合物 |
| CN106573006A (zh) * | 2014-08-21 | 2017-04-19 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为药物的rip1激酶抑制剂杂环酰胺 |
| EP3372604B1 (en) * | 2015-11-05 | 2021-12-01 | Sumitomo Chemical Company, Limited | Condensed heterocyclic compound |
| WO2018017435A1 (en) | 2016-07-22 | 2018-01-25 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof |
| EP3575298B1 (en) | 2017-01-24 | 2022-03-02 | Sumitomo Chemical Company, Limited | Fused heterocyclic compound and composition containing same |
| EP3580220B1 (en) * | 2017-02-13 | 2021-11-17 | Bristol-Myers Squibb Company | Aminotriazolopyridines as kinase inhibitors |
| WO2019089442A1 (en) | 2017-10-30 | 2019-05-09 | Bristol-Myers Squibb Company | Aminoimidazopyridines as kinase inhibitors |
| MX2020007531A (es) | 2018-01-26 | 2020-09-09 | Bristol Myers Squibb Co | Aminopirrolotriazinas como inhibidores de cinasa. |
| AR123793A1 (es) * | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
-
2018
- 2018-02-12 EP EP18707498.4A patent/EP3580220B1/en active Active
- 2018-02-12 CN CN201880024064.1A patent/CN110520423B/zh active Active
- 2018-02-12 ES ES18707498T patent/ES2902676T3/es active Active
- 2018-02-12 HU HUE18707498A patent/HUE057801T2/hu unknown
- 2018-02-12 PT PT187074984T patent/PT3580220T/pt unknown
- 2018-02-12 MX MX2019009555A patent/MX378515B/es unknown
- 2018-02-12 PL PL18707498T patent/PL3580220T3/pl unknown
- 2018-02-12 JP JP2019543377A patent/JP7097373B2/ja active Active
- 2018-02-12 US US16/484,604 patent/US10913738B2/en active Active
- 2018-02-12 MA MA047460A patent/MA47460A/fr unknown
- 2018-02-12 SM SM20220001T patent/SMT202200001T1/it unknown
- 2018-02-12 LT LTEPPCT/US2018/017755T patent/LT3580220T/lt unknown
- 2018-02-12 SG SG11201907335UA patent/SG11201907335UA/en unknown
- 2018-02-12 DK DK18707498.4T patent/DK3580220T3/da active
- 2018-02-12 SI SI201830511T patent/SI3580220T1/sl unknown
- 2018-02-12 WO PCT/US2018/017755 patent/WO2018148626A1/en not_active Ceased
- 2018-02-12 AU AU2018217488A patent/AU2018217488B2/en not_active Ceased
- 2018-02-12 BR BR112019016635A patent/BR112019016635A2/pt not_active Application Discontinuation
- 2018-02-12 RS RS20220021A patent/RS62801B1/sr unknown
- 2018-02-12 HR HRP20212000TT patent/HRP20212000T1/hr unknown
- 2018-02-12 KR KR1020197026464A patent/KR102549952B1/ko active Active
- 2018-02-12 CA CA3053484A patent/CA3053484A1/en active Pending
- 2018-02-12 EA EA201991915A patent/EA039808B1/ru unknown
-
2019
- 2019-08-09 IL IL268614A patent/IL268614B/en unknown
-
2020
- 2020-12-09 US US17/116,016 patent/US12157733B2/en active Active
-
2022
- 2022-01-18 CY CY20221100043T patent/CY1124978T1/el unknown
-
2024
- 2024-10-28 US US18/928,275 patent/US20250074909A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12157733B2 (en) | Aminotriazolopyridines as kinase inhibitors | |
| EP3704118B1 (en) | Aminoimidazopyridazines as kinase inhibitors | |
| US11618753B2 (en) | Aminopyrrolotriazines as kinase inhibitors | |
| KR102793119B1 (ko) | 키나제 억제제로서의 인다졸 카르복스아미드 | |
| EP3849968B1 (en) | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) | |
| WO2016100166A1 (en) | SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-c]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS | |
| TW202233614A (zh) | 作為激酶抑制劑之三唑并吡啶化合物 | |
| KR102906523B1 (ko) | 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드 | |
| NZ793902A (en) | Substituted 2-azabicycles and their use as orexin receptor modulators | |
| EA042124B1 (ru) | Аминоимидазопиридазины в качестве ингибиторов киназ | |
| CN119431317A (zh) | 一种作为抗病毒的三聚氯氰三取代的胺类衍生物、其制备方法及用途 |